title: Norgestrel, increased lipids: fact or "marketing monster"?
mesh_terms: D000569:Americas; D001157:Arterial Occlusive Diseases; D001161:Arteriosclerosis; D001695:Biology; D003267:Contraception; D003270:Contraceptive Agents; D003271:Contraceptive Agents, Female; D003276:Contraceptives, Oral; D003277:Contraceptives, Oral, Combined; D003278:Contraceptives, Oral, Hormonal; D019049:Developed Countries; D004194:Disease; D004997:Ethinyl Estradiol; D005193:Family Planning Services; D016912:Levonorgestrel; D008055:Lipids; D009640:Norethindrone; D009644:Norgestrel; D009656:North America; D010827:Physiology; D014481:United States; D014652:Vascular Diseases
chemical_list: D003270:Contraceptive Agents; D003271:Contraceptive Agents, Female; D003276:Contraceptives, Oral; D003277:Contraceptives, Oral, Combined; D003278:Contraceptives, Oral, Hormonal; D008055:Lipids; D009644:Norgestrel; D004997:Ethinyl Estradiol; D016912:Levonorgestrel; D009640:Norethindrone
keywords: Americas; Arterial Occlusive Diseases; Arteriosclerosis; Atherosclerosis; Biology; Contraception; Contraceptive Agents; Contraceptive Agents, Estrogen; Contraceptive Agents, Female; Contraceptive Agents, Progestin; Contraceptive Methods; Developed Countries; Diseases; Ethinyl Estradiol; Family Planning; Levonorgestrel; Lipid Metabolic Effects; Lipids; Norethindrone; Norgestrel; North America; Northern America; Oral Contraceptives; Oral Contraceptives, Combined; Oral Contraceptives, Phasic; Physiology; United States; Vascular Diseases